Genmab — Juli 2016
-
Sad lige og legede lidt med kuglerammen...med et topsalg på 15 mia. Plus lidt mere end darazalex i pipeline og en P/E på 18 kommer kursen jo omkring de 5000.... Er det helt forkert ?
-
-
http://www.abeldanger.net/2015/03/death-drugs-and-hsba-how-fraudulent.html Lidt oplysninger om HSBC
-
http://finance.yahoo.com/news/goldman-hsbc-sued-over-metals-201502313.html;_ylt=A9mSs3Gyd35XvQEAQy8wFIpQ;_ylu=X3oDMTByMWk2OWNtBGNvbG8DaXIyBHBvcwMyBHZ0aWQDBHNlYwNzcg-- HSBC samarbejder sørme med selveste Goldman Sachs
-
Havde ikke set denne - http://www.investor.jnj.com/eventdetail.cfm?EventID=174007#
-
Valuation & Risks: Buy, PT up to DKK1440 from DKK1400
We update our model for FX which increases our DCF-derived price target slightly to DKK1440 from DKK1400. We use a WACC of 8.5% (RFR 3.5%, ERP 5.5%, beta 0.9) and TGR of 2.5%, in lin
e with the sector. Key risks are: (1) Regulatory hurdles for Darzalex; (2) Competitor data; 3) Pipeline failure.
(daratumumab) Phase 3 data and Janssen Immuno-Oncology Strategy Webcast
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind